Loading...
•
Jun 30, 2021
AbCellera Q2 2021 Earnings Report
Reported strong growth across key performance indicators related to the partnership business, including new programs under contract, program starts, and new molecules in the clinic.
Key Takeaways
AbCellera reported Q2 2021 financial results with a total revenue of $27.6 million, up from $11 million in Q2 2020. The company incurred a net loss of $2.3 million, compared to net earnings of $6.7 million in Q2 2020.
Earned $27.6 million in total revenue, including $22.2 million in milestones and royalties.
Incurred net loss of $2.3 million, compared to generating net earnings of $6.7 million in Q2 2020.
Added 19 programs under contract with four new partners, resulting in a cumulative total of 138 programs under contract with 33 different partners.
Confirmed three new molecules advanced into the clinic, bringing the cumulative total to four.
AbCellera
AbCellera
AbCellera Revenue by Segment
Revenue by Segment
Research Fees Revenue
CapyFin.comLicensing Revenue
CapyFin.comRevenue & Expenses
Visualization of income flow from segment revenue to net income